Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
13
02
2019
accepted:
21
11
2019
pubmed:
30
11
2019
medline:
28
4
2021
entrez:
30
11
2019
Statut:
ppublish
Résumé
Chronic inflammation is a key pathological hallmark of multiple sclerosis (MS) and suggests that resolution of inflammation, orchestrated by specialized pro-resolving lipid mediators (LM), is impaired. Here, through targeted-metabololipidomics in peripheral blood of patients with MS, we revealed that each disease form was associated with distinct LM profiles that significantly correlated with disease severity. In particular, relapsing and progressive MS patients were associated with high eicosanoids levels, whereas the majority of pro-resolving LM were significantly reduced or below limits of detection and correlated with disease progression. Furthermore, we found impaired expression of several pro-resolving LM biosynthetic enzymes and receptors in blood-derived leukocytes of MS patients. Mechanistically, differentially expressed mediators like LXA
Identifiants
pubmed: 31780628
pii: haematol.2019.219519
doi: 10.3324/haematol.2019.219519
pmc: PMC7395264
doi:
Substances chimiques
Eicosanoids
0
Inflammation Mediators
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2056-2070Subventions
Organisme : NIGMS NIH HHS
ID : P01 GM095467
Pays : United States
Informations de copyright
Copyright© 2020 Ferrata Storti Foundation.
Références
Mol Aspects Med. 2017 Dec;58:57-64
pubmed: 28456616
J Immunol. 2011 Aug 15;187(4):1957-69
pubmed: 21724996
J Leukoc Biol. 2017 Feb;101(2):531-542
pubmed: 27630217
Prostaglandins Leukot Essent Fatty Acids. 2017 Feb;117:17-27
pubmed: 28237084
EMBO Mol Med. 2013 May;5(5):762-75
pubmed: 23584892
Sci Transl Med. 2016 Aug 24;8(353):353ra111
pubmed: 27559094
Proc Natl Acad Sci U S A. 1989 Jun;86(12):4720-4
pubmed: 2734316
Prog Neurobiol. 2011 Jan;93(1):1-12
pubmed: 20946934
N Engl J Med. 2000 Sep 28;343(13):938-52
pubmed: 11006371
Nat Commun. 2019 Sep 2;10(1):3945
pubmed: 31477726
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
Redox Biol. 2017 Aug;12:438-455
pubmed: 28319894
Immunol Cell Biol. 2014 Jul;92(6):509-17
pubmed: 24638064
Mult Scler. 1998 Jun;4(3):162-8
pubmed: 9762667
Eur J Pharmacol. 2016 Aug 15;785:156-164
pubmed: 26325092
Am J Physiol Cell Physiol. 2014 Dec 1;307(11):C1058-67
pubmed: 25273880
Oxid Med Cell Longev. 2019 Jun 18;2019:8107265
pubmed: 31316721
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Prostaglandins Leukot Essent Fatty Acids. 2005 Nov;73(5):397-404
pubmed: 16099630
FASEB J. 2008 Oct;22(10):3595-606
pubmed: 18559988
Front Immunol. 2018 Jan 29;9:38
pubmed: 29434586
Am J Respir Crit Care Med. 2002 Jun 1;165(11):1531-5
pubmed: 12045128
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Alzheimers Dement. 2015 Jan;11(1):40-50.e1-2
pubmed: 24530025
Int J Neurosci. 2013 Nov;123(11):792-800
pubmed: 23713615
Eur J Immunol. 2015 Jun;45(6):1808-19
pubmed: 25756873
Curr Top Med Chem. 2014;14(22):2590-9
pubmed: 25478879
Antioxid Redox Signal. 2005 Nov-Dec;7(11-12):1744-54
pubmed: 16356135
Nat Rev Neurosci. 2015 Mar;16(3):147-58
pubmed: 25697158
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Acta Neuropathol. 2014 Nov;128(5):691-703
pubmed: 25149081
Pharmacol Res. 2016 Nov;113(Pt A):313-319
pubmed: 27616551
Nat Commun. 2018 Jan 4;9(1):59
pubmed: 29302056
Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20560-5
pubmed: 23185003
Mol Aspects Med. 2017 Dec;58:114-129
pubmed: 28336292
PLoS One. 2013;8(2):e55859
pubmed: 23409068
Am J Physiol Cell Physiol. 2012 Apr 1;302(7):C968-78
pubmed: 22205391
Biochim Biophys Acta. 2016 Mar;1862(3):461-71
pubmed: 26527183
Cell. 2010 Mar 19;140(6):871-82
pubmed: 20303877
Lancet Neurol. 2015 Feb;14(2):183-93
pubmed: 25772897
FASEB J. 2015 Jun;29(6):2504-13
pubmed: 25777995
J Biol Chem. 2015 Dec 25;290(52):30697-712
pubmed: 26546682
Nat Commun. 2016 Sep 23;7:12859
pubmed: 27659679
Brain. 2011 Feb;134(Pt 2):555-70
pubmed: 21183485
Oxid Med Cell Longev. 2013;2013:185715
pubmed: 24381712
J Immunol. 2009 Mar 15;182(6):3819-26
pubmed: 19265161
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
J Immunol. 2012 Sep 1;189(5):2597-605
pubmed: 22844113
Arch Med Res. 2014 Nov;45(8):687-97
pubmed: 25431839
Innate Immun. 2016 Apr;22(3):186-95
pubmed: 26878867
Am J Pathol. 2015 Dec;185(12):3189-201
pubmed: 26468975
ScientificWorldJournal. 2011 May 05;11:1056-67
pubmed: 21552771
FASEB J. 2011 Jul;25(7):2399-407
pubmed: 21478260
Mol Neurobiol. 2016 May;53(4):2733-49
pubmed: 26650044
Fluids Barriers CNS. 2013 Mar 26;10(1):16
pubmed: 23531482
FASEB J. 2015 Jul;29(7):2681-9
pubmed: 25805829
FASEB J. 2016 Aug;30(8):2662-72
pubmed: 27118674